Unusual 11 Mid-Day Movers 9/21: (GALT) (CONN) (BIOA) Higher; (MSTX) (MIRN) (PCRX) Lower
- Wall Street flat as telecom gains fail to counter oil drop
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Deal Progress Said to Slow as Johnson & Johnson (JNJ) Puts Actelion (ALIOY) Under Microscope - Source
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Galectin Therapeutics (Nasdaq: GALT) 25.1% HIGHER; moving higher once again as speculators reprice NASH stocks following Allergen's takeover of Tobira yesterday.
Mirna Therapeutics, Inc. (Nasdaq: MIRN) 21.1% LOWER; announced its decision to close the ongoing Phase 1 study of MRX34, its investigational microRNA therapy for multiple cancers. The Company voluntarily halted enrollment and dosing in the clinical study following multiple immune-related severe adverse events (SAE) observed in patients dosed with MRX34 over the course of the trial.
Conn's Inc. (Nasdaq: CONN) 20.0% HIGHER; Stifel upgraded Conn's Inc. from Hold to Buy with a price target of $16.00.
BioAmber Inc. (NYSE: BIOA) 13.8% HIGHER; announced an important milestone in its application for a $360 million loan guarantee from the U.S. Department of Energy (U.S. DOE). This loan guarantee is in connection with the Company's goal of securing non-dilutive funding for its proposed second manufacturing facility that would be located in the United States.
Cerecor Inc. (Nasdaq: CERC) 13.0% HIGHER; announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-301, Clin301-203, as an oral, rapidly acting adjunctive treatment of major depressive disorder. The Company now expects to report top-line data from this trial in November 2016.
Abeona Therapeutics Inc. (Nasdaq: ABEO) 12.1% HIGHER; announced the exclusive worldwide license of a next generation gene therapy AAV capsid portfolio from University of North Carolina at Chapel Hill.
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) 11.6% HIGHER; announced that top-line data from the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) will be presented as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. Presented data will include a biomarker in the SUNRISE trial that correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO 2016 Congress, which is being held October 7-11, 2016 in Copenhagen, Denmark.
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) 10.4% LOWER; announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that provides prolonged non-opioid postsurgical pain control.
CareDx, Inc. (Nasdaq: CDNA) 9.3% LOWER; announced the pricing of its public offering of 2.25 million shares of its common stock at a price to the public of $4.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 337,500 additional shares of its common stock. All of the shares will be offered and sold by CareDx.
Skechers USA (NYSE: SKX) 9.1% LOWER; Morgan Stanley downgraded Skechers USA from Overweight to Equalweight with a price target of $25.00 (from $41.00). Analyst Jay Sole noted that consumer's preferred athletic footwear styles are shifting toward pure fashion. As Sketchers adjusts its assortment, he sees slower sales and increasing SG&A. Overall he thinks risk/reward looks balanced.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Notable Analyst Rating Changes 12/6: (P) (STLD) (NFLX) Upgraded; (NKE) (CBB) (ISBC) Downgraded
- Notable Analyst Rating Changes 12/1: (DE) (WLL) (SMTC) Upgraded; (NOV) (MCD) (CERN) Downgraded
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold